Association between bullous pemphigoid and psoriasis: A case-control study

doi:10.1016/j.jaad.2017.02.057

Journal of the American Academy of Dermatology

Volume 77, Issue 2, August 2017, Pages 370-372

https://doi.org/10.1016/j.jaad.2017.02.057 Get rights and content

First page preview

Click to open first page preview

View PDF

References (5)

C. Ohata et al.
Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: a series of 145 cases
J Am Acad Dermatol
(2015)
P. Joly et al.
Incidence and mortality of bullous pemphigoid in France
J Invest Dermatol
(2012)

There are more references available in the full text version of this article.

Cited by (28)

Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature
2023, International Immunopharmacology
Bullous pemphigoid (BP) and psoriasis are both immune-related skin diseases. Still, the comorbidities between the two are rare, and there is no consensus on the optimal treatment strategy for BP combined with psoriasis. JAK inhibitors are emerging, molecularly targeted therapeutic agents that target the molecule of Janus kinase, a signal transducer and activator of transcription (JAK/STAT). JAK inhibitors block intracellular signaling pathways by blocking the gene transcription of key pro-inflammatory cytokines that play a central role in the pathogenesis of many inflammatory and autoimmune diseases. Tofacitinib is a first-generation JAK inhibitor. The purpose of this article is to describe the first report of the use of tofacitinib in treating BP combined with psoriasis vulgaris with significant results. According to our findings, tofacitinib may be a safe and effective treatment option for patients suffering from BP and psoriasis together. The implications of this are substantial for the guidance of treatment strategies for both comorbid conditions.
Neutrophil-rich, noncollagenous 16A domain-negative bullous pemphigoid associated with psoriasis
2021, JAAD Case Reports
Citation Excerpt :
The association between psoriasis and BP has been described in several studies,2 and BP is 3.05 times more likely to develop in psoriatic patients than in matched controls. Notably, psoriasis preceded the development of BP in all patients in a case-control study.10 Additional reports of NC16A domain-negative BP and concurrent psoriasis have been documented in the literature.1,7
A new eruption of bullous pemphigoid within psoriatic plaques following cyclosporine withdrawal
2021, JAAD Case Reports
Citation Excerpt :
Autoantibody complement fixation leads to dermal inflammatory infiltrate with C3 and IgG deposition in the BMZ and formation of tense blisters.2 Multiple case-control studies have demonstrated an increased prevalence of BP in psoriasis patients compared with controls.2,3 Although isolated BP typically presents after the age of 70, it often develops earlier in patients with a history of psoriasis.3
Dermatitis Herpetiformis and Celiac Disease Increase the Risk of Bullous Pemphigoid
2019, Journal of Investigative Dermatology
Citation Excerpt :
However, due to its rapid effect on pruritus, dapsone is frequently used in the initiation of therapy and in patients whose symptoms persist despite the gluten-free diet (Bolotin and Petronic-Rosic, 2011b; Reunala et al., 2015; Collin et al., 2017). Neurologic conditions are well known to be associated with BP, and psychiatric diseases, psoriasis, hypertension, hematologic malignancies, and diabetes have also been reported as comorbidities of BP (Atzmony et al., 2017; Chen et al., 2011; Kibsgaard et al., 2017; Kridin and Bergman, 2017; Schulze et al., 2015; Sim et al., 2017). DH is associated with type I diabetes, thyroid diseases, and other autoimmune diseases (Bolotin and Petronic-Rosic, 2011a; Collin et al., 2017).
Bullous pemphigoid (BP) and dermatitis herpetiformis (DH) are autoimmune bullous skin diseases. DH has been described to evolve into BP and the two diseases can have overlapping clinical appearances and diagnostic findings, but the association between DH and BP has not previously been studied in a large population. To evaluate DH and celiac disease as risk factors for BP, we conducted a retrospective case-control study of patients with BP and matched controls with basal cell carcinoma diagnosed in Finland between 1997 and 2013. A total of 3,397 patients with BP and 12,941 controls were included in the study. Forty-one (1.2%) BP patients and 7 (0.1%) controls had preceding DH. Diagnosed DH increased the risk of BP 22-fold (odds ratio = 22.30; 95% confidence interval = 9.99–49.70) and celiac disease 2-fold (odds ratio = 2.54; 95% confidence interval = 1.64–3.92) compared to controls. Eighteen (43.9%) of the patients who had DH and subsequent BP had bought dapsone during the 2 years prior to their BP diagnosis. Mean time between diagnosed DH and BP was 3 years. We conclude that diagnosis of DH is associated with a striking increase in the risk for BP.
Causal association between psoriasis vulgaris and bullous pemphigoid: a two-sample bidirectional Mendelian randomization study
2024, Frontiers in Immunology
Psoriasiform and lichenoid eruptions as a potential harbinger of bullous dermatoses in the setting of immune checkpoint inhibitors: a case series
2023, International Journal of Dermatology

View all citing articles on Scopus

: Funding sources: None.

: Conflicts of interest: None declared.

View full text

Research letterAssociation between bullous pemphigoid and psoriasis: A case-control study

First page preview

J Am Acad Dermatol

J Invest Dermatol

Research letter
Association between bullous pemphigoid and psoriasis: A case-control study